Is a complete IMMX research report available?

No complete published report is available for Immix Biopharma, Inc. (IMMX) on this page. Market-directory data, when present, is not a substitute for a reviewed stock analysis.

Immix Biopharma, Inc. (IMMX)

NASDAQ: IMMX · USD

$8.55

+0.38 (+4.7%)· Recorded snapshot

Coverage state: Market snapshot only — no published research

Market snapshot recorded 2026-07-31 02:00 UTC. No published research is attached to this ticker. Prices and fundamentals on this server-rendered page are dated snapshots, not a real-time trading feed.

On-demand research

Generate the first IMMX analysis

Start the full research workflow when this ticker is ready in our data system.

Market cap	608.7M
Net income (ttm)	-35M
EPS (ttm)	-$0.89
Shares out	71.2M
Volume	1,298,311
Beta	0.09
Price target	$19.9	+132.9%

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -35M
EPS (ttm): -$0.89
Market cap: 608.7M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ALNY	Alnylam Pharmaceuticals, Inc.	27.4B	36.9x	5.7x	96.6%	+47.5%	-37.8%	Strong Buy
ARGX	argenx SE	53.8B	31.3x	10.1x	50.6%	+58.8%	+45.7%	Strong Buy
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

All IMMX indicators

Market & fundamental data

Available fields

180

Groups with data

Currency

USD

Showing 180 of 180 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001873835
Company name	Immix Biopharma, Inc.
Country	United States
Country code	US
Cusip	45258H106
Employees	21
Employees Change	4%
Employees Change Percent	23.53
Enterprise value	$519.1M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2021-12-16
Isin	US45258H1068
Last refreshed	2026-07-31
Market cap	$608.7M
Market cap category	Small-Cap
Price	$8.55
Price currency	USD
Sector	Healthcare
Sector PE	45.21
Sector PE Fwd	23.64
Sic	2834
Symbol	IMMX
Website	https://www.immixbio.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-5.75%
FCF yield	-5.38%
P/B ratio	5.37x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Net Income	$-35M
Net Income Growth Years	0%
Profit Per Employee	$-1.7M
ROA	-38.97
Roa5y	-38.68
ROCE	-42.31
ROE	-74.47
Roe5y	-145.8
ROIC	-46.95

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	216.92%
Cagr3y	61.21%
EPS Growth Years	0
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$95.8M
Cash	$90.6M
Current Assets	$92.3M
Current Liabilities	$10.5M
Debt	$1M
Debt Equity	$0.01
Equity	$84.4M
Liabilities	$11.5M
Long Term Assets	$3.5M
Long Term Liabilities	$912,343
Net Cash	$89.5M
Net Cash By Market Cap	$14.71
Net Cash Growth	502.48%
Net Debt Equity	$-1.06
Tangible Book Value	$84.4M
Tangible Book Value Per Share	$1.59
WACC	4.73

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	8.76
Net Working Capital	$-8.7M
Quick ratio	8.59
Working Capital	$81.7M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-31.93%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	216.67%
200-day SMA	7.37
3Y total return	319.12%
50-day SMA	9.31
50-day SMA vs 200-day SMA	50over200
All Time High	12.14
All Time High Change	-29.57%
All Time High Date	2026-07-07
All Time Low	0.68
All Time Low Change	1,157.35%
All Time Low Date	2022-11-10
ATR	0.78
Beta	0.09
Beta1y	0.61
Beta2y	1.28
Ch YTD	63.48
High	8.63
High52	12.14
High52 Date	2026-07-07
High52ch	-29.57%
Low	8.26
Low52	1.94
Low52 Date	2025-09-17
Low52ch	340.72%
Ma50ch	-8.14%
Price vs 200-day SMA	15.95%
RSI	41.74
RSI Monthly	67.05
RSI Weekly	51.4
Sharpe ratio	1.72x
Sortino ratio	2.95
Total Return	-31.93%
Tr YTD	63.48
Tr1m	-18.49%
Tr1w	-2.84%
Tr3m	-0.93%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	7
Analyst Count Top	5
Analyst Price Target Top	$20.4
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$-0.17
Operating Income	$-36.1M
Price target	$19.91
Price Target Change	$133
Price Target Change Top	$139

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	56,781,084%
Float Percent	79.76%
Shares Insiders	9.55%
Shares Institutions	42.53%
Shares Out	71,189,951
Shares Qo Q	37.65%
Shares Yo Y	31.93%
Short Float	14.97%
Short Ratio	3.62
Short Shares	11.94

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-34.9M
Adjusted OCF	-34,221,438
Average Volume	1,844,985.7x
Bv Per Share	1.59
CAPEX	$-697,698
Ch1m	-18.49
Ch1w	-2.84
Ch1y	216.7
Ch3m	-0.93
Ch3y	319.1
Ch6m	43.7
Change	4.65%
Change From Open	3.26
Close	8.17
Days Gap	1.35
Depreciation Amortization	299,171
Dollar Volume	11,100,559.1
Earnings Date	2026-08-10
Earnings Time	amc
EBIT	$-36.1M
EBITDA	$-35.6M
EPS	$-0.89
F Score	2
FCF	$-32.8M
FCF EV Yield	-6.31x
FCF Per Share	$-0.46
Financing CF	107,349,298
Fiscal Year End	December
Founded	2,014
Income Tax	$27,902
Investing CF	-11,946,908
Ipr	71
Iprfo	71
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-07
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-03-25
Ma150	8.42
Ma150ch	1.54%
Ma20	9.85
Ma20ch	-13.2%
Net CF	63,329,062
Next Earnings Date	2026-08-11
Open	8.28
Optionable	Yes
Position In Range	78.38
Post Close	8.55
Postmarket Change Percent	0.82
Postmarket Price	$8.62
Ppne	3,356,105
Price Date	2026-07-30
Ptbv Ratio	7.21
Relative Volume	0.7x
Share Based Comp	2,149,081
Tr6m	43.7%
Us State	California
Volume	1,298,311

Immix Biopharma, Inc. (IMMX)

Coverage state: Market snapshot only — no published research

Generate the first IMMX analysis

Price

Financial snapshot

Fair-value bridge

Analyst consensus

Latest news · IMMX

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All IMMX indicators

Profile and market data

Valuation

Profitability

Growth

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Analyst estimates

Ownership and float

Other indicators

Deeper analysis on IMMX

Frequently asked questions